ILMN•prnewswire•
Illumina and MyOme Strike Collaboration Deal Including Strategic Investment to Support MyOme's Clinical Trial That Could Save U.S. Healthcare $200 Billion Annually
Summary
Partnership unites Illumina's leading sequencing technology with cutting-edge clinical genomics analyses and AI to advance precision medicine for early detection and prevention. SAN DIEGO and MENLO PARK, Calif., Dec. 11, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) and MyOme, a...
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on December 11, 2025 by prnewswire